The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Cipla Q3 Profit Surges 49% to Rs 1,571 Crore Cipla's net profit for Q3 FY25 jumped 49% to Rs 1,571 crore, driven by growth across markets. Revenue rose to Rs 7,073 crore. Read more. Jan 28, 2025 16:23 ...

Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing developing and marketing wide range of branded and generic formulations and Active ...

Drug major Cipla reported a 49% year-on-year jump in its December quarter consolidated net profit, reaching Rs 1,571 crore, compared to Rs 1,056 crore in the same period last year. The profit after ...

Cipla finished the day at Rs 1464.15, showing a fall of 1.22% in its market value. Cipla's shares are currently priced at Rs 1465.95, reflecting a 1.09% decrease today, alongside a return of 3.38% ...

Cipla Q3 results review: The shares of the third largest pharmaceutical firm Cipla rose 2.44 per cent at Rs 1,454.20 a piece on the BSE intraday after the company delivered a solid quarterly earnings ...

Mumbai: Cipla Limited has announced that the Company has completed an investment of approx. ZAR 900 million in Cipla Medpro South Africa Proprietary Limited, South Africa, a wholly owned subsidiary in ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

Cipla Ltd.'s consolidated net profit rose 49% year-on-year in the third quarter of the current financial year, beating analysts' estimates by a substantial margin. The drugmaker posted a consolidated ...

HYDERABAD/BENGALURU (Reuters) -Cipla, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by strong domestic demand, and said the U.S ...

At ₹1,571 crore, Cipla has reported a 49% year-on-year increase in net profits between October and December 2024. The pharma giant’s revenue from operations is ₹7,073 crore, compared to ...